Samsung Bioepis

Privately held: no public share price

Assets

(5 total)
5Total Assets
5Approved
0Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-AProtein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.